Black Diamond Therapeutics Files 8-K
Ticker: BDTX · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1701541
| Field | Detail |
|---|---|
| Company | Black Diamond Therapeutics, Inc. (BDTX) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: BDTX
TL;DR
BDTX filed an 8-K for financial updates, nothing major in the excerpt.
AI Summary
On March 12, 2024, Black Diamond Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along with financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Black Diamond Therapeutics is providing updates on its financial condition and operations to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial reporting and does not disclose any new material risks or events.
Key Players & Entities
- Black Diamond Therapeutics, Inc. (company) — Registrant
- 0001701541-24-000009 (dollar_amount) — Accession Number
- March 12, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-39200 (company) — SEC File Number
- 81-4254660 (company) — IRS Employer Identification No.
- One Main Street, 14th Floor Cambridge, MA 02142 (location) — Address of principal executive offices
- 617-252-0848 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Black Diamond Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
What is the accession number for this filing?
The accession number for this filing is 0001701541-24-000009.
On what date was this 8-K report filed?
This 8-K report was filed on March 12, 2024.
In which state was Black Diamond Therapeutics, Inc. incorporated?
Black Diamond Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Black Diamond Therapeutics, Inc.?
The principal executive office address is One Main Street, 14th Floor, Cambridge, MA 02142.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-03-12 07:17:49
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BDTX The Nasdaq Glo
Filing Documents
- bdtx-20240312.htm (8-K) — 26KB
- bdtx-exhibit991_q42023.htm (EX-99.1) — 61KB
- logo.jpg (GRAPHIC) — 14KB
- 0001701541-24-000009.txt ( ) — 234KB
- bdtx-20240312.xsd (EX-101.SCH) — 2KB
- bdtx-20240312_lab.xml (EX-101.LAB) — 22KB
- bdtx-20240312_pre.xml (EX-101.PRE) — 13KB
- bdtx-20240312_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 12, 2024, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release issued by Black Diamond Therapeutics, Inc., dated March 12 , 202 4 . SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Black Diamond Therapeutics, Inc. Date: March 12, 2024 By: /s/ Brent Hatzis-Schoch Brent Hatzis-Schoch Chief Operating Officer and General Counsel